Hyaluronic Acid Fuels Pancreatic Cancer Growth
Kim, P. K.; Halbrook, C. J.; Kerk, S. A.; Wisner, S.; Kremer, D. M.; Sajjakulnukit, P.; Hou, S. W.; Thurston, G.; Anand, A.; Yan, L.; Salamanca-Cardona, L.; Welling, S. D.; Zhang, L.; Pratt, M. R.; Keshari, K. R.; Ying, H.; Lyssiotis, C. A.
Show abstract
Rewired metabolism is a hallmark of pancreatic ductal adenocarcinomas (PDA). Previously, we demonstrated that PDA cells enhance glycosylation precursor biogenesis through the hexosamine biosynthetic pathway (HBP) via activation of the rate limiting enzyme, glutamine-fructose 6-phosphate amidotransferase 1 (GFAT1). Here, we genetically ablated GFAT1 in PDA cell lines, which completely blocked proliferation in vitro and led to cell death. In contrast, GFAT1 knockout did not impair tumor growth, suggesting that cancer cells can maintain fidelity of glycosylation precursor pools by scavenging nutrients from the tumor microenvironment. Here, we show that hyaluronic acid (HA), an abundant carbohydrate polymer in pancreatic tumors composed of repeating N-acetyl-glucosamine (GlcNAc) and glucuronic acid sugars, can bypass GFAT1 to refuel the HBP via the GlcNAc salvage pathway. Furthermore, HA facilitates proliferation in nutrient-starved wild-type PDA. Together, these data show HA can serve as a nutrient fueling PDA metabolism beyond its previously appreciated structural and signaling roles.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblastdriven nutritional support and immunosuppression 97%
- Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression 96%
- Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer 96%
Similar papers in this journal
- Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1 97%
- Ki-67 promotes sequential stages of tumourigenesis by enabling cellular plasticity 95%
- A Targeted Combination Therapy Achieves Effective Pancreatic Cancer Regression And Prevents Tumor Resistance 95%
Similar papers in this journal
- The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. 97%
- Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels 96%
- HIRA loss transforms FH-deficient cells 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.